Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biomarin Pharmac Shares Down 37.6% Since SmarTrend's Sell Call (BMRN)

SmarTrend identified a Downtrend for Biomarin Pharmac (NASDAQ:BMRN) on July 30th, 2020 at $119.85. In approximately 2 months, Biomarin Pharmac has returned 37.64% as of today's recent price of $74.73....

BMRN : 79.38 (+1.30%)
BioMarin to Participate in Four Upcoming Virtual Investor Conferences

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences.  An audio webcast of the presentations will be available...

JPM : 98.35 (-0.21%)
MS : 50.08 (-0.34%)
BMRN : 79.38 (+1.30%)
BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that , MD, MS, for Biomedical Innovation at Harbor-UCLA Medical Center, , USA will present data from the randomized, double-blind,...

BMRN : 79.38 (+1.30%)
Opthea Appoints US-Based Non-Executive Director

The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, are pleased to announce the...

BMRN : 79.38 (+1.30%)
MYGN : 12.93 (+3.11%)
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN

Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN

ILMN : 295.50 (-0.85%)
BMRN : 79.38 (+1.30%)
CCJ : 10.48 (-3.50%)
PFSW : 6.45 (-4.44%)
BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data Demonstrating Statistically Significant Increase in Annualized Growth Velocity (AGV) Over 52 Weeks in Children with Achondroplasia

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that has published online results from a randomized, double-blind, phase 3, placebo-controlled, multicenter trial for vosoritide,...

BMRN : 79.38 (+1.30%)
BioMarin to Participate in Two Upcoming Virtual Investor Conferences

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available...

BMRN : 79.38 (+1.30%)
These 4 Stocks Could Be Toxic for Your Portfolio

Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.

ILMN : 295.50 (-0.85%)
BMRN : 79.38 (+1.30%)
CCJ : 10.48 (-3.50%)
PFSW : 6.45 (-4.44%)
Biomarin Pharmac Shares Down 36.6% Since SmarTrend's Sell Call (BMRN)

SmarTrend identified a Downtrend for Biomarin Pharmac (NASDAQ:BMRN) on July 30th, 2020 at $119.85. In approximately 1 month, Biomarin Pharmac has returned 36.58% as of today's recent price of $76.00.

BMRN : 79.38 (+1.30%)
BioMarin Pharmaceutical (BMRN) Gains As Market Dips: What You Should Know

BioMarin Pharmaceutical (BMRN) closed at $76 in the latest trading session, marking a +0.21% move from the prior day.

BMRN : 79.38 (+1.30%)
Shares of BMRN Down 34.7% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Biomarin Pharmac (NASDAQ:BMRN) on July 30th, 2020 at $119.85. In approximately 1 month, Biomarin Pharmac has returned 34.67% as of today's recent price of $78.29.

BMRN : 79.38 (+1.30%)
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates

The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.

BMRN : 79.38 (+1.30%)
MRNA : 69.87 (+2.92%)
BMY : 59.27 (-0.22%)
AMGN : 247.72 (-0.15%)
VRTX : 265.39 (-2.24%)
NVAX : 108.36 (-6.19%)
Biomarin Pharmac Set to Possibly Pullback After Yesterday's Rally of 2.67%

Biomarin Pharmac (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $74.24 to a high of $77.24. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high...

BMRN : 79.38 (+1.30%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN

Pomerantz LLP is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN). Such investors are advised to contact Robert S. Willoughby...

BMRN : 79.38 (+1.30%)
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.

BMRN : 79.38 (+1.30%)
EBS : 100.59 (-1.02%)
HZNP : 79.93 (+2.53%)
ASND : 147.00 (+0.89%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN

Pomerantz LLP is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN). Such investors are advised to contact Robert S. Willoughby...

BMRN : 79.38 (+1.30%)
BioMarin Down on CRL From FDA for Hemophilia A Candidate

BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.

PFE : 36.63 (-0.52%)
BMRN : 79.38 (+1.30%)
SGMO : 10.82 (+0.37%)
QURE : 41.69 (+0.02%)
BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia

, /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vosoritide, an investigational,...

BMRN : 79.38 (+1.30%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).  Such investors are advised to contact...

BMRN : 79.38 (+1.30%)
FDA blocks much-anticipated BioMarin hemophilia gene therapy

FAIRLESS HILLS, PA (AP) — Investors fled drug developer BioMarin in droves on Wednesday, driving shares down by a third after U.S. regulators rejected the company’s potentially game-changing hemophilia...

PFE : 36.63 (-0.52%)
NVS : 90.94 (-0.03%)
BMRN : 79.38 (+1.30%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar